Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Bicycle Therapeutics plc
Headquarters: Cambridge, United Kingdom
Website: http://www.bicycletherapeut...
Year Founded: 2009
Status: Public
Industry Sector: HealthTechnology
CEO: Kevin Lee, PhD, MBA
Number Of Employees: 305
Enterprise Value: $-55,120,698
PE Ratio: -3.19
Exchange/Ticker 1: NASDAQ:BCYC
Exchange/Ticker 2: N/A
Latest Market Cap: $634,674,304
BioCentury | Feb 13, 2025
Management Tracks
Lee joins Lycia as CMO
Plus: Firth joins Panacea, Lakewood appoints Manion chair and updates from Ai Proteins, Cognito and Kala
BioCentury | Dec 31, 2024
Finance
Biotech raises make 2024 the year of the PIPE
BioCentury’s final Public Equity Report of the year tallies up fundraising activity
BioCentury | Dec 18, 2024
Product Development
Merck, iTeos dropping assets, Viridian data — BioCentury’s Clinical Report
Plus: Readouts from Sanofi-Teva, Bicycle and more
BioCentury | Nov 20, 2024
Deals
Where the Ratio deal fits into Novartis’ radiopharma matrix
The deal grows Novartis’ ligand modality and chelator toolbox, and its focus on Lutathera target SSTR2
BioCentury | Oct 15, 2024
Finance
Forbion’s European capital wave
Sticking to its strategy, firm raises $2.2B just 18 months after raising $1.5B
BioCentury | Aug 7, 2024
Management Tracks
Flagship adds White House veteran Panjabi
Plus: Biogen alum Radhakrishnan joins Sofinnova Investments, and updates from Bicycle, iTeos, Fennec, Faron and ORIC
BioCentury | Jun 18, 2024
Product Development
Tumor cell surface targets off the beaten path
Beyond the headlines at ASCO and AACR were a set of less traveled cancer targets, including neuronal proteins hijacked by solid tumors
BioCentury | May 24, 2024
Finance
Public Equity Report: Investors see Cytokinetics’ moves as doubt for M&A
Plus: IPO updates from Sunho, Rapport; Bicycle’s massive PIPE; Dyne’s opportunistic follow-on; and more
BioCentury | Mar 21, 2024
Management Tracks
Novartis’ Hanekamp to lead commercial at BioNTech
Plus: New leaders for Bayer’s commercial team and updates from Intra-Cellular, Affyimmune, BenevolentAI, Bicycle and VolitionRx
Items per page:
1 - 10 of 61